자기 혈당 측정 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, self-Monitoring blood glucose market size in 2026 is estimated at USD 16.42 billion, growing from 2025 value of USD 15.47 billion with 2031 projections showing USD 22.11 billion, growing at 6.14% CAGR over 2026-2031.

This report is Segmented by Product Type (Glucose Meters, and More), Technology (Electrochemical and Photometric), Modality (Hand-Held Conventional and Wearable), Application (Type 1 Diabetes, and More), End-User (Hospitals, and More), Distribution Channel (Retail Pharmacies, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Self-Monitoring Blood Glucose Market Trends and Insights

Escalating Global Diabetes Prevalence

International agencies warn that diabetes cases surpassed 800 million adults in 2024 and could hit 1.31 billion by 2025, amplifying the imperative for frequent glucose checks. Type 2 diabetes represents 96% of diagnoses, with high body-mass index driving more than half of related disability-adjusted life years. Annual direct medical spending linked to diabetes is projected at USD 413 billion, prompting insurers to emphasize early intervention using reliable self-monitoring devices. Consensus guidelines released in 2025 reinforce structured testing as foundational to avoid complications. The scale of the burden ensures that even incremental gains in testing penetration translate into substantial unit demand.

Shift Toward Home-Based Glucose Management

COVID-19 catalyzed a broad redesign of care pathways, normalizing home-use meters for both inpatient and outpatient monitoring under emergency protocols later made permanent by regulators. Evidence linking self-testing to 0.3-0.5 percentage-point reductions in HbA1c has convinced physicians to endorse more frequent home checks for insulin and non-insulin users alike. Remote meter readings transmitted to clinicians support medication titration without clinic visits, lowering costs for payers while improving convenience. Manufacturers are countersinking test-strip subsidies into integrated meter-and-app bundles to deepen patient engagement and defend pricing.

Intensifying Price Pressure on Test Strips

Generic strips and private-label pharmacy offerings have eroded average selling prices by 5-7% annually since 2023 in mature markets. With strips accounting for roughly three-quarters of total revenue, margin compression is steering incumbents toward volume-based tactics or migration to premium connected ecosystems. Pharmacy benefit managers conduct annual tenders that intensify competition, forcing manufacturers to bundle coaching apps and extended warranties to defend shelf space. Large players are exploring backward integration into enzyme production to recapture cost advantages.

Other drivers and restraints analyzed in the detailed report include:

1. Expanded Reimbursement for SMBG Supplies
2. Digital Integration with Tele-Diabetes Platforms
3. Stringent Regulatory Compliance Hurdles

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Test strips generated 76.12% of Self-Monitoring Blood Glucose market revenue in 2025, propelled by the necessity for multiple daily measurements among insulin users. This consumable model insulates suppliers from hardware replacement cycles, though commoditization has narrowed unit margins. Strip innovations now target capillary volumes below 0.4 µL and 5-second read times to boost adherence. The Self-Monitoring Blood Glucose market size tied to glucose meters is expanding swiftly which deliver 10.85% forecast CAGR through 2031, offering richer data and value-added services that justify premiums. Manufacturers partner with smartphone-app developers to merge nutrition logs, step counts, and medication reminders, enhancing differentiation. Efforts to minimize strip environmental footprint-bioplastic housings and corrugated paper packaging-address rising consumer sustainability expectations.

Second-generation strips incorporate multi-electrode designs that cross-check hematocrit and ambient temperature, cutting user error. Suppliers bundle loyalty programs that discount bulk packs, locking patients into proprietary ecosystems. Conversely, healthcare systems in lower-income regions still prioritize affordability over connectivity, sustaining basic strip demand even as unit prices slip.

Electrochemical sensors underpin 89.30% of devices sold, testament to decades of reliability and cost efficiency. Their enzyme-mediated current output correlates linearly with glucose concentration, simplifying calibration. Continued miniaturization using carbon-nanotube electrodes enables thinner, shorter strips that require less blood. Photometric methods hold only a modest share today yet post the highest growth trajectory at 9.45% owing to optical chips that promise non-enzymatic detection and potential sweat-based applications. The Self-Monitoring Blood Glucose market share advantage of electrochemical platforms remains secure until optical accuracy and unit economics converge.

Researchers are experimenting with surface-enhanced Raman spectroscopy to resolve interstitial glucose yet face challenges such as skin-tone variability and signal-to-noise. Hybrid meters that incorporate both electrochemical and photometric modules are emerging, offering redundancy and facilitating transition paths for users. Regulatory agencies mandate tight mean absolute relative difference thresholds; thus, new technologies must surpass electrochemical benchmarks to gain clinical legitimacy.

Complete Report Scope:

• By Product Type
  • Glucose Meters
  • Test Strips
  • Lancets
• By Technology
  • Electrochemical
  • Photometric
• By Modality
  • Hand-held Conventional
  • Wearable / Connected
• By Application
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Prediabetes
• By End-user
  • Hospitals & Clinics
  • Home-care Settings
  • Diagnostic Laboratories
  • Ambulatory Surgical Centers
• By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Others
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 39.45% of 2025 revenue, anchored by the United States where diabetes prevalence stood at 11.3% of adults and healthcare spend per capita remains the world's highest. Medicare and private insurers reimburse both meter hardware and supplies, sustaining sizeable Self-Monitoring Blood Glucose market share and funding next-generation connected devices. Canada mirrors these dynamics, although provincial formularies emphasize price caps on strips, spurring growth of lower-cost brands. Widespread 4G/5G coverage underpins tele-diabetes platforms that integrate meter feeds directly into electronic health records.

Europe ranks second, with Germany alone holding more than one quarter of regional revenue in 2025. Statutory insurance schemes reimburse unlimited strips for insulin users, driving volumes despite fierce tender-led price erosion. Environmental directives such as the European Green Deal elevate scrutiny of single-use plastic components, prompting suppliers to introduce recyclable cartridges and take-back pilots. Nations like Sweden and France have begun factoring carbon-footprint metrics into procurement scoring, offering early-mover advantages to eco-forward brands.

Asia-Pacific is the fastest-growing region at 9.18% CAGR through 2031. China's adult diabetes prevalence of 10.9% translates into more than 140 million potential users; domestic manufacturers leverage scale to supply low-priced strips, while foreign brands compete on accuracy and connectivity. India's expanding middle class and government health insurance schemes such as Ayushman Bharat widen access, yet rural distribution gaps persist. Smartphone penetration exceeding 70% across urban Southeast Asia accelerates adoption of app-linked meters. Local language interfaces and cloud servers hosted within national borders address regulatory and cultural preferences, facilitating uptake.

1. Abbott Laboratories
2. Roche
3. Lifescan
4. Ascensia
5. Arkray
6. Terumo Corp.
7. i-SENS Inc.
8. Nova Biomedical
9. Bionime
10. AgaMatrix
11. Acon Laboratories
12. Trividia Health
13. Rossmax
14. Ypsomed
15. OK Biotech Co. Ltd.
16. SD Biosensor Inc.
17. Sinocare
18. B. Braun
19. A. Menarini Diagnostics (GlucoMen)
20. Beurer

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Escalating Global Diabetes Prevalence And Earlier Diagnostic Rates
  • 4.2.2 Shift Toward Home-Based, Patient-Empowered Glucose Management
  • 4.2.3 Expanding Third-Party Reimbursement And Insurance Coverage For SMBG Supplies Across Major Economies
  • 4.2.4 Rising Disposable Income And Diabetes Awareness In High-Growth Emerging Markets
  • 4.2.5 Integration Of SMBG Data With Digital Health & Tele-Diabetes Platforms Driving Value-Added Services
• 4.3 Market Restraints
  • 4.3.1 Intensifying Price Competition And Commoditization Of Test Strips Compressing Margins
  • 4.3.2 Stringent Regulatory & Quality-Compliance Requirements Prolonging Product Approval Timelines
  • 4.3.3 Environmental And Waste-Management Concerns Over Single-Use Strips And Lancets
• 4.4 Supply-Chain Analysis
• 4.5 Technological Outlook
• 4.6 Porter's Five Forces
  • 4.6.1 Bargaining Power of Suppliers
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Threat of New Entrants
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Glucose Meters
  • 5.1.2 Test Strips
  • 5.1.3 Lancets
• 5.2 By Technology
  • 5.2.1 Electrochemical
  • 5.2.2 Photometric
• 5.3 By Modality
  • 5.3.1 Hand-held Conventional
  • 5.3.2 Wearable / Connected
• 5.4 By Application
  • 5.4.1 Type 1 Diabetes
  • 5.4.2 Type 2 Diabetes
  • 5.4.3 Gestational Diabetes
  • 5.4.4 Prediabetes
• 5.5 By End-user
  • 5.5.1 Hospitals & Clinics
  • 5.5.2 Home-care Settings
  • 5.5.3 Diagnostic Laboratories
  • 5.5.4 Ambulatory Surgical Centers
• 5.6 By Distribution Channel
  • 5.6.1 Retail Pharmacies
  • 5.6.2 Hospital Pharmacies
  • 5.6.3 Online Pharmacies
  • 5.6.4 Others
• 5.7 Geography
  • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
  • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
  • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
    • 5.7.3.4 Australia
    • 5.7.3.5 South Korea
    • 5.7.3.6 Rest of Asia-Pacific
  • 5.7.4 Middle East and Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East and Africa
  • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 F. Hoffmann-La Roche AG
  • 6.3.3 LifeScan Inc.
  • 6.3.4 Ascensia Diabetes Care
  • 6.3.5 ARKRAY Inc.
  • 6.3.6 Terumo Corp.
  • 6.3.7 i-SENS Inc.
  • 6.3.8 Nova Biomedical
  • 6.3.9 Bionime Corporation
  • 6.3.10 AgaMatrix Inc.
  • 6.3.11 ACON Laboratories
  • 6.3.12 Trividia Health
  • 6.3.13 Rossmax International
  • 6.3.14 Ypsomed AG
  • 6.3.15 OK Biotech Co. Ltd.
  • 6.3.16 SD Biosensor Inc.
  • 6.3.17 Sinocare Inc.
  • 6.3.18 B. Braun Melsungen AG
  • 6.3.19 A. Menarini Diagnostics (GlucoMen)
  • 6.3.20 Beurer GmbH

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment